A Kansas case in which a doctor is accused of unlawfully prescribing Cephalon (CEPH)'s Actiq painkiller among other drugs, leading to the fatal overdoses of fifty-six patients, sheds some light on ...

Valeant's (VRX) hostile takeover bid for Cephalon (CEPH) is certainly living up to the "hostile" part: A slideshow it made for investors basically says, "You suck, Cephalon. Hand over your shares ...

Drug maker Cephalon Inc. sent letters to doctors this week warning them that several deaths have been linked to Fentora, its powerful narcotic to treat acute cancer pain. Fentora and its ...

It was an awful Monday for Cephalon. One disappointing drug trial caused the company's stock to plunge. When the market closed, the stock was down 36% from its previous close of $62.75 ...

To resolve a spate of whistleblower lawsuits, drug manufacturer Cephalon has agreed to pay $431 million in civil and criminal fines for illegally promoting "off-label" uses for three of its drugs ...

From setting unrealistically high sales quotas to pushing larger prescriptions at higher doses, drug maker Cephalon Inc. engaged in questionable practices to expand sales of Actiq, a powerful ...

The arrangement involved an outside joint venture formed last December with two of Cephalon's institutional investors. The investors put up $50 million in exchange for equity in the venture ...

By Rebecca R. Ruiz and Katie Thomas A lawsuit claimed that Cephalon, a subsidiary of Teva Pharmaceuticals, had paid generic manufacturers to keep a cheaper version of a drug off the market.

Teva Pharmaceutical Industries Ltd.’s Cephalon unit and Acusphere Inc. sued Celgene Corp. for patent infringement related to the breast cancer drug Abraxane. The lawsuit claims Celgene’s ...

FRAZER, Pa. Cephalon has completed its acquisition of Swiss drug maker Mepha, Cephalon announced Friday. The $615.4 million acquisition makes Mepha a wholly owned subsidiary of Cephalon.